RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma

NCT01189240 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

13

Enrollment

NIH

Sponsor class

Stopped Company decided to stop development of drug - 7/31/12

Conditions

Adult Anaplastic Astrocytoma
Adult Anaplastic Oligodendroglioma
Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Tumor

Interventions

DRUG: gamma-secretase/Notch signalling pathway inhibitor RO4929097
BIOLOGICAL: bevacizumab
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)